Drug firm Laurus Labs today said it has received the establishment inspection report (EIR) from the US health regulator after inspection of a unit of the company's Achutapuram facility in Vishakhapatnam.
The company has received the EIR from the US Food and Drug Administration (USFDA) for its finished dosage formulations and active pharmaceutical ingredients manufacturing plant, unit two at Achutapuram, Laurus Labs said in a filing to the BSE.
The inspection of the facility was completed in May 2017, it added.
Shares of Laurus Labs Ltd today closed at Rs 549.80 per scrip on BSE, up 0.04 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)